Valuation: electroCore, Inc.

Capitalization 54.12M 46.16M 42.33M 40.07M 74.26M 5.18B 74.97M 504M 196M 2.46B 203M 199M 8.54B P/E ratio 2026 *
-4.42x
P/E ratio 2027 * -9.61x
Enterprise value 54.12M 46.16M 42.33M 40.07M 74.26M 5.18B 74.97M 504M 196M 2.46B 203M 199M 8.54B EV / Sales 2026 *
1.28x
EV / Sales 2027 * 0.99x
Free-Float
63.84%
Yield 2026 *
-
Yield 2027 * -
1 day+1.29%
1 week-4.22%
Current month+2.84%
1 month+10.12%
3 months+19.77%
6 months+10.48%
Current year+49.28%
1 week 6.16
Extreme 6.16
6.88
1 month 5.85
Extreme 5.85
7.34
Current year 4.45
Extreme 4.45
8.3
1 year 4.16
Extreme 4.16
8.64
3 years 3.83
Extreme 3.8285
19.49
5 years 2.92
Extreme 2.925
27.75
10 years 2.92
Extreme 2.925
303.75
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 63 2017-04-30
Director of Finance/CFO - 2024-09-30
Chief Operating Officer - 2026-04-12
Director TitleAgeSince
Chairman 74 2025-09-01
Director/Board Member 65 2020-04-01
Director/Board Member 62 2020-04-01
Change 5d. change 1-year change 3-years change Capi.($)
+1.29%-4.22%+38.90%+2.84% 54.12M
+0.34%-0.33%+8.48%+0.73% 12.7B
+0.03%-0.02%+9.16%+3.43% 9.35B
+0.82%+2.37%-1.03%-24.82% 5.58B
+1.01%-0.57%+45.72%+27.97% 5.48B
+1.96%-0.96%-14.39%+40.79% 4.88B
-1.09%+1.95%-16.03%-8.21% 4.39B
+6.54%+1.80% - - 3.34B
+1.16%+15.30%-1.40%-75.59% 2.12B
-2.68%+1.62%+5.63%-42.89% 1.66B
Average +0.94%+1.83%+8.34%-8.42% 4.95B
Weighted average by Cap. +0.80%+1.36%+6.63%-0.26%

Financials

2026 *2027 *
Net sales 42.38M 36.15M 33.15M 31.38M 58.16M 4.06B 58.71M 395M 154M 1.92B 159M 156M 6.69B 54.71M 46.66M 42.79M 40.51M 75.07M 5.24B 75.79M 510M 198M 2.48B 205M 201M 8.63B
Net income -13.86M -11.82M -10.84M -10.26M -19.02M -1.33B -19.2M -129M -50.28M -629M -52.01M -50.91M -2.19B -6.94M -5.92M -5.43M -5.14M -9.53M -665M -9.62M -64.69M -25.19M -315M -26.06M -25.51M -1.1B
Net Debt - -
Logo electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Employees
83
Date Price Change Volume
26-05-12 6.695 $ +1.29% 70,690
26-05-11 6.610 $ +3.12% 61,636
26-05-08 6.410 $ +2.23% 71,003
26-05-07 6.270 $ -5.86% 62,282
26-05-06 6.660 $ -4.72% 19,171
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.695USD
Average target price
19.57USD
Spread / Average Target
+192.31%

Quarterly revenue - Rate of surprise